Brucellosis treated with rifampicin

Area of Science:

• Pediatric Infectious Diseases
• Bacterial Infections
• Pharmacology

Background:

• Brucellosis is a significant zoonotic infection affecting children worldwide.
• Treatment of pediatric brucellosis requires effective and safe antimicrobial regimens.
• Rifampicin has shown promise in treating various bacterial infections.

Purpose of the Study:

• To evaluate the efficacy and safety of oral rifampicin monotherapy in children with brucellosis.
• To determine the optimal treatment duration and dosage for pediatric brucellosis.
• To assess the need for combination therapy in treating pediatric brucellosis.

Main Methods:

• A prospective study involving 14 pediatric patients diagnosed with brucellosis.
• Diagnosis confirmed by blood culture, serum agglutination, complement-fixation, and Coomb's tests.
• Treatment administered orally with rifampicin (20 mg/kg/day) for 3 weeks.

Main Results:

• All 14 children showed a good clinical response, with fever resolution within 2-8 days.
• Brucella melitensis was identified in 11 cases via blood culture.
• Two children experienced relapses, one possibly due to reinfection; both responded well to combined rifampicin and co-trimoxazole therapy.

Conclusions:

• Oral rifampicin monotherapy is effective in treating pediatric brucellosis, leading to rapid clinical improvement.
• Relapses can occur, and combination therapy with co-trimoxazole may be advisable for improved outcomes.
• Further research into optimal combination regimens for pediatric brucellosis is warranted.